BIOSCIENCE Trial Further Confirms Orsiro as Best in Class
The BIOTRONIK Stent is the only Vascular Intervention Product Featured in this Year’s ESC Hot Line Sessions
BARCELONA, Spain, September 1, 2014 – Late-breaking results of the BIOSCIENCE study were announced today in a Hot Line session at the ESC Congress by study investigator Dr. Thomas Pilgrim, University Clinic for Cardiology, Bern, Switzerland. The independent study was intended to confirm the safety and efficacy of Orsiro, the world’s first Hybrid Drug-Eluting Stent. The BIOTRONIK stent represents the only vascular intervention technology to have been accepted into the elite Hot Line sessions at ESC. The announcement of Orsiro’s excellent results will be accompanied by publication in the prestigious The Lancet journal, yet more evidence that this highly innovative product is truly best in class.BIOSCIENCE is an investigator initiated, multi-center, randomized, controlled, all-comers non-inferiority study. It is the largest published industry-independent comparison to date evaluating the safety and efficacy of a sirolimus-eluting stent with a biodegradable polymer and an everolimus-eluting stent with a durable polymer. For the study, each device was used in the treatment of patients undergoing percutaneous coronary intervention in routine clinical practice. BIOSCIENCE confirms and builds on results from several clinical trials demonstrating the excellence of Orsiro, including the recent BIOFLOW-II trial, which demonstrated the safety and efficacy of Orsiro against Abbott’s Xience Prime. BIOSCIENCE compares these two products once again, but this time with a primary clinical endpoint in a much larger population of 2119 patients.“The results of the BIOSCIENCE trial show that in a large patient population reflecting routine clinical practice, Orsiro, with its ultra-thin strut, is as safe and efficacious as the thin-strut Xience Prime," commented Dr. Pilgrim during his presentation. “'The observed benefit in the pre-specified subgroup with ST-segment elevation myocardial infarction warrants further study.”The primary endpoint of the study was Target Lesion Failure (TLF), defined as a composite of cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (MI) and clinically driven Target Lesion Revascularization (TLR) at 12 months. Encouragingly, primary endpoint results from the 12-month follow-up demonstrated that Orsiro met its study objective of non-inferiority versus Xience Prime, hence performing as best in class.“We are particularly proud to see Orsiro doing so well in an all-comers trial with a large, real-world patient population and a clinical endpoint,” commented Dr. Daniel Bühler, President Vascular Intervention at BIOTRONIK. “Our aim is to provide physicians with the most innovative, reliable tools available. The results of BIOSCIENCE show that Orsiro is a Masterpiece—one that physicians can rely on when giving patients the very best treatment.”
At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular and endovascular solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.